ArticleCancers2026

Reduced-Dose Regorafenib for Recurrent Glioblastoma: A Safety and Outcome Analysis.

Massimiliano Domenico Rizzaro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.